Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary results from a randomized controlled trial.
Mac Giollabhui N, Mischoulon D, Dunlop BW, Kinkead B, Schettler PJ, Liu RT, Okereke OI, Lamon-Fava S, Fava M, Rapaport MH. Mac Giollabhui N, et al. Among authors: fava m. Brain Behav Immun Health. 2023 Jul 7;32:100666. doi: 10.1016/j.bbih.2023.100666. eCollection 2023 Oct. Brain Behav Immun Health. 2023. PMID: 37503359 Free PMC article.
Association of a polymorphism near CREB1 with differential aversion processing in the insula of healthy participants.
Perlis RH, Holt DJ, Smoller JW, Blood AJ, Lee S, Kim BW, Lee MJ, Sun M, Makris N, Kennedy DK, Rooney K, Dougherty DD, Hoge R, Rosenbaum JF, Fava M, Gusella J, Gasic GP, Breiter HC; Phenotype Genotype Project on Addiction and Mood Disorders. Perlis RH, et al. Among authors: fava m. Arch Gen Psychiatry. 2008 Aug;65(8):882-92. doi: 10.1001/archgenpsychiatry.2008.3. Arch Gen Psychiatry. 2008. PMID: 18678793 Free PMC article.
Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study.
Schmidt ME, Kezic I, Popova V, Melkote R, Van Der Ark P, Pemberton DJ, Mareels G, Canuso CM, Fava M, Drevets WC. Schmidt ME, et al. Among authors: fava m. Neuropsychopharmacology. 2024 Apr 22. doi: 10.1038/s41386-024-01862-x. Online ahead of print. Neuropsychopharmacology. 2024. PMID: 38649428
Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study.
Rutrick D, Stein DJ, Subramanian G, Smith B, Fava M, Hasler G, Cha JH, Gasparini F, Donchev T, Ocwieja M, Johns D, Gomez-Mancilla B. Rutrick D, et al. Among authors: fava m. Adv Ther. 2017 Feb;34(2):524-541. doi: 10.1007/s12325-016-0468-5. Epub 2017 Jan 2. Adv Ther. 2017. PMID: 28044255 Clinical Trial.
1,161 results